A new study has found that psilocybin may be more effective than the antidepressant escitalopram (an SSRI) in treating ...

STIM recently announced that additional payors have updated the coverage of TMS (transcranial magnetic stimulation). This upgrade is aimed at reducing the access barriers for patients with major ...

Here's a look at the best and worst states in each of the four data categories: mental health provider ratio, suicide rate ...

Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the ...

Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) ...

The first long-term comparison of psilocybin vs an SSRI for MDD suggests the psychedelic was associated with better overall ...

RIM-TD open-label extension (OLE) study showed long-term improvement of Tardive Dyskinesia (TD) symptoms from treatment with deutetrabenazine ...

This study aimed to explore the association between major depressive disorder (MDD) and suicide risk in dementia patients.A cohort of 625,218 individuals aged ≥40 years with dementia between 2007 and ...

Pediatric patients are also more susceptible to becoming addicted to ketamine and forming substance abuse disorders.

A study comparing psilocybin to the SSRI escitalopram found both drugs improved depressive symptoms similarly over six months ...

Dysthymia, now more commonly referred to as Persistent Depressive Disorder (PDD), is a chronic form of depression ...

Neuronetics, Inc. (NASDAQ: STIM) this week announced significant progress in expanding access to its NeuroStar TMS Therapy ...